<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>X4 Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc</link>
<description>Latest news and press releases for X4 Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/x4-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835db8a78dffbe2df123ecb.webp</url>
<title>X4 Pharmaceuticals Inc</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc</link>
</image>
<item>
<title>X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-european-commission-approval-of-xolremdir-mavorixafor-the-first-and-only-authorized-treatment-for-patients-with-whim-syndrome-in-the-european-union</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-european-commission-approval-of-xolremdir-mavorixafor-the-first-and-only-authorized-treatment-for-patients-with-whim-syndrome-in-the-european-union</guid>
<pubDate>Wed, 29 Apr 2026 11:00:00 GMT</pubDate>
<description>- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, announced today that the European Commission (EC) has granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with W</description>
</item>
<item>
<title>X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 17 Mar 2026 11:15:00 GMT</pubDate>
<description>- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for the Treatment of WHIM Syndrome in the European Union - - Balance Sheet Provides Cash Runway through 2028 - BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results</description>
</item>
<item>
<title>X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-leerink-global-healthcare-conference-7</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-leerink-global-healthcare-conference-7</guid>
<pubDate>Wed, 04 Mar 2026 12:00:00 GMT</pubDate>
<description>BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management team will participate in a fireside chat at the Leerink Global Healthcare Conference on Wednesday, March 11, 2026 at 10:00 a.m. ET in Miami, FL. A link to the live and archived webcast may be accessed on X4 Pharmaceuticals’ website under the Investors section: Events and Presentations. About X4 Pharmace</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Mon, 02 Mar 2026 21:30:00 GMT</pubDate>
<description>BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on February 27, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of</description>
</item>
<item>
<title>X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-receives-positive-opinion-from-the-ema-chmp-recommending-approval-of-mavorixafor-in-the-eu-for-whim-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-receives-positive-opinion-from-the-ema-chmp-recommending-approval-of-mavorixafor-in-the-eu-for-whim-syndrome</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a</description>
</item>
<item>
<title>X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-participate-guggenheim-emerging-120000928</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-participate-guggenheim-emerging-120000928</guid>
<pubDate>Tue, 03 Feb 2026 12:00:00 GMT</pubDate>
<description>BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be available under</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-210100970</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-210100970</guid>
<pubDate>Mon, 02 Feb 2026 21:01:00 GMT</pubDate>
<description>BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employ</description>
</item>
<item>
<title>X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-participate-guggenheim-second-210100103</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-participate-guggenheim-second-210100103</guid>
<pubDate>Wed, 05 Nov 2025 21:01:00 GMT</pubDate>
<description>BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston. The X4 team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be avail</description>
</item>
<item>
<title>X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-reports-third-quarter-120000847</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-reports-third-quarter-120000847</guid>
<pubDate>Wed, 05 Nov 2025 12:00:00 GMT</pubDate>
<description>Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trialPreviously announced workforce reductions resulted in $13M annualized cost savingsSuccessful completion of two financial transactions totaling $240.3M; cash runway now extends to the end of 2028 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today reported financial results</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-closing-public-230500516</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-closing-public-230500516</guid>
<pubDate>Mon, 27 Oct 2025 23:05:00 GMT</pubDate>
<description>BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 6,984,000 additional shares, at a public offering price per share of $2.90 and, in lieu of common stock to certain inve</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-pricing-135-043700986</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-pricing-135-043700986</guid>
<pubDate>Fri, 24 Oct 2025 04:37:00 GMT</pubDate>
<description>BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering pri</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Proposed Underwritten Public Offering</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-proposed-underwritten-200100676</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-proposed-underwritten-200100676</guid>
<pubDate>Thu, 23 Oct 2025 20:01:00 GMT</pubDate>
<description>BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, X4 expects to grant the underwriters an option for a period of 30 days to purchase</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-restructuring-business-110000868</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-restructuring-business-110000868</guid>
<pubDate>Wed, 17 Sep 2025 11:00:00 GMT</pubDate>
<description>Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President Dr. Adam Craig, Executive Chairman, to have oversight over clinical development BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced a strat</description>
</item>
<item>
<title>Sitryx appoints Adam Mostafa as Chief Financial Officer</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/sitryx-appoints-adam-mostafa-as-chief-financial-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/sitryx-appoints-adam-mostafa-as-chief-financial-officer-1</guid>
<pubDate>Mon, 08 Sep 2025 11:00:00 GMT</pubDate>
<description>Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective t</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Fri, 15 Aug 2025 04:00:00 GMT</pubDate>
<description>BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-closing-upsized-110000428</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-closing-upsized-110000428</guid>
<pubDate>Wed, 13 Aug 2025 11:00:00 GMT</pubDate>
<description>BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares of common stock for total offering proceeds of $85 million. The originally announced offering of $60 million was increased to allow for the inclusion of an investor who had a pre-existing investment ri</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-60-million-110000183</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-60-million-110000183</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it has entered into a securities purchase a</description>
</item>
<item>
<title>X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-presents-positive-phase-120000601</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-presents-positive-phase-120000601</guid>
<pubDate>Mon, 16 Jun 2025 12:00:00 GMT</pubDate>
<description>Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce injectable G-CSF while maintaining ANC levels in the normal range Data continue to strengthen confidence in potential success of ongoing global, pivotal Phase 3 trial evaluating mavorixafor in primary chronic neutropenia BOSTON, June 16, 2025 (GLOBE NEWSWI</description>
</item>
<item>
<title>X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-granted-fast-track-120000192</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-granted-fast-track-120000192</guid>
<pubDate>Tue, 10 Jun 2025 12:00:00 GMT</pubDate>
<description>BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain primary CN conditions. Mav</description>
</item>
<item>
<title>X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress</title>
<link>https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-upcoming-presentation-201200095</link>
<guid isPermaLink="true">https://6ix.com/company/x4-pharmaceuticals-inc/news/x4-pharmaceuticals-announces-upcoming-presentation-201200095</guid>
<pubDate>Wed, 14 May 2025 20:12:00 GMT</pubDate>
<description>Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster present</description>
</item>
</channel>
</rss>